Highly complementary Williston Basin and Delaware Basin assets enhance Crestwood’s competitive positioning in its core growth basins Significantly expands Crestwood’s leading position in the...
Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc. PR Newswire LAVAL, Quebec, April 25, 2013 LAVAL, Quebec, April 25, 2013 /PRNewswire/ -- Valeant...
Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc. PR...
Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc. PR...
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc. PR Newswire MONTREAL, April 22, 2013...
Merz Pharma Group Withdraws Proposal to Acquire Obagi Medical Products PR Newswire FRANKFURT, Germany, April 8, 2013 FRANKFURT, Germany, April 8, 2013 /PRNewswire/ -- Merz Pharma Group...
NEW YORK, April 3, 2013 (GLOBE NEWSWIRE) -- In a press release issued today by Levi & Korsinsky with the same headline, please note that the per share amount in the third paragraph should be...
NEW YORK, April 3, 2013 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors of Obagi Medical Products, Inc. ("Obagi" or the "Company") (Nasdaq:OMPI) of claims of breaches of fiduciary duty...
Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash PR Newswire MONTREAL, April 3, 2013 MONTREAL, April 3, 2013 /PRNewswire/...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約